Tiziana Life Sciences Ltd.

TLSA · Nasdaq · United Kingdom

Share price · TLSA

$0.81-0.31 (-27.82%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.3M (2.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TLSA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+24.8%
  2. 2 Nov 2026-16.2%
  3. 30 Sep 2026+16.4%
  4. 23 Sep 2026+18.0%
  5. 17 Sep 2026+26.0%
  6. 24 Jul 2026-12.5%

    Nothing announced by TLSA that day or the session before.

  7. 15 Jul 2026-10.5%
  8. 13 Jul 2026+8.1%

    Nothing announced by TLSA that day or the session before.

  9. 6 Jul 2026-10.7%
  10. 3 Jun 2026-13.2%

Share of unusual movement by asset

For each asset, the share of TLSA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Foralumab
events and moves
7shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—60%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
CD3Monoclonal antibody
Multiple SclerosisAmyotrophic Lateral Sclerosis
Secondary Progressive Multiple Sclerosis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
ForalumabPhase 2Multiple System Atrophy
Est. primary completion 2027-04-01 · NCT06868628 · CT.gov ↗
What to watch
July 2027 (1)
ForalumabPhase 2ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
Est. primary completion 2027-07 · NCT07688239 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 November 2026Topline resultForalumabPhase 2a INFORM-MS met its dual primary endpoints

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$5.2M$3.7M$3.0M-$1.5M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY—$8.1M$1.2M$4.4M-$16M operating cash flowreport ↗
2022-FY—$13M$18M$3.9M-$20M operating cash flowreport ↗
2021-FY—$13M$42M$5.9M-$22M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 5 purchases ($1.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-15Elrifi Ivor · Chief Executive OfficerOption exercise1,050,000——Form 4
2026-08-15Elrifi Ivor · Chief Executive OfficerOption exercise (derivative)1,050,000——Form 4
2026-08-05Elrifi Ivor · Chief Executive OfficerOpen-market purchase237,616$1.00$238KForm 4
2026-08-04Elrifi Ivor · Chief Executive OfficerOpen-market purchase83,807$0.97$81KForm 4
2026-08-03Elrifi Ivor · Chief Executive OfficerOpen-market purchase667,000$1.00$667KForm 4
2026-07-21CERRONE GABRIELE M · director, 10% ownerOpen-market purchase42,357$0.99$42KForm 4
2026-07-21CERRONE GABRIELE M · director, 10% ownerAward / grant42,357$0.99$42KForm 4
2026-06-12CERRONE GABRIELE M · director, 10% ownerOpen-market purchase15,000$1.11$17KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 3.1M shares ($3.7M).

#InstitutionSharesValue
1Dauntless Investment Group, LLC2,165,231$2.5M
2MARSHALL WACE, LLP157,566$184K
3Zhang Financial LLC111,900$131K
4UBS Group AG95,700$112K
5Focus Partners Wealth79,365$93K
6GEODE CAPITAL MANAGEMENT, LLC78,204$91K
7GOLDMAN SACHS GROUP INC75,660$89K
8HSBC HOLDINGS PLC62,437$76K
9MORGAN STANLEY52,156$61K
10EWA, LLC45,948$54K
11CITADEL ADVISORS LLC35,094$41K
12XTX Topco Ltd28,500$33K
13JANE STREET GROUP, LLC24,047$28K
14SUSQUEHANNA INTERNATIONAL GROUP, LLP17,267$20K
15Rachor Investment Advisory Services, LLC17,000$20K